» » Eylea, as Compared to Avastin or Lucentis, Provides Greater Visual Improvement for Diabetic Macular Edema

Eylea, as Compared to Avastin or Lucentis, Provides Greater Visual Improvement for Diabetic Macular Edema

Eylea (aflibercept), as compared to Avastin (bevacizumab) or Lucentis (ranibizumab), provided greater visual improvement for diabetic macular edema (DME), when vision was 20/50 or worse at the start of the NIH-supported clinical trial. However, investigators found that all the three drugs resulted in similar average improvement when starting vision was 20/40 to 20/32, and nor did they find any major differences in the safety of the three drugs. This comparative effectiveness ...

Read More
You have just read an article categorized health titled Eylea, as Compared to Avastin or Lucentis, Provides Greater Visual Improvement for Diabetic Macular Edema.
Written by: editor - Thursday, February 19, 2015

There are currently no comments for "Eylea, as Compared to Avastin or Lucentis, Provides Greater Visual Improvement for Diabetic Macular Edema"

Post a Comment

Subscribe to: Post Comments (Atom)